GoodRx Q4 2022 Earnings Report
Key Takeaways
GoodRx reported Q4 2022 total revenue of $184.1 million, exceeding guidance. Subscription revenue grew 42% year-over-year. Over 7 million Americans used GoodRx for their healthcare needs in the fourth quarter.
Total revenue of $184.1 million, exceeding previously announced guidance.
Net loss of $2.01 million; Net loss margin of 1.1%.
Adjusted EBITDA of $49.6 million; Adjusted EBITDA Margin of 26.9%, exceeding previously announced guidance.
Exited the quarter with over 7 million consumers of prescription-related offerings.
GoodRx
GoodRx
Forward Guidance
For the first quarter and full year 2023, management is anticipating total revenue of approximately $181 million to $183 million for Q1 and $780 million to $790 million for the full year. Adjusted EBITDA margin for the first quarter and full year 2023 is expected to be in the mid-twenty-percent range.
Positive Outlook
- Focus on efficiently growing profitability
- Steady margin improvement
- Executing on strong cash conversion
- Balance sheet maintains a strong cash and liquidity position
- Aiding our capital allocation priorities to support our realigned organization in driving highly efficient and profitable growth
Challenges Ahead
- Q1 2023 total revenue includes a $35 million to $45 million estimated impact to prescription transactions revenue related to the grocer issue.
- Uncertainty and potential variability of stock-based compensation expense
- Acquired intangible assets and related amortization
- Income taxes
- Targeted and strategic marketing investments over the course of the year, which are factored into our margin guidance for the first quarter.